As if the atrocities on Medical Professionals was not enough, The Competition Commission of India ( CCI), India’s fair trade regulator, has locked its sights on unfair practices in the country’s billion-dollar pharmaceuticals and healthcare sectors, calling for proposals to study the nature and magnitude of the problem. The decision comes amid concerns of a continued nexus between companies, doctors and hospitals that keeps patients from accessing high quality, affordable treatment here.
The body has submitted a request for proposals from agencies to conduct a study on the sector that would help it eliminate anti-competitive practices, protect interests of patients and ensure freedom of trade in this industry. “In the enforcement experience of the Commission, several anti-competitive practices in the Indian pharmaceutical and healthcare sector have come to the fore,” stated CCI in its…
